SkinBioTherapeutics Wins Shareholder Backing for Growth and Capital Authorities at AGM

An update from SkinBioTherapeutics ( (GB:SBTX) ) is now available.

SkinBioTherapeutics reported that all resolutions at its Annual General Meeting were passed, including the receipt of accounts, reappointment and fee-setting authority for its auditor, and broad authorities for directors to allot shares and equity securities, including on a non-pre-emptive basis and in connection with acquisitions or other capital investments. The voting outcomes, which showed strong but not unanimous support across all items, confirm shareholder backing for the company’s current governance, financing flexibility and acquisition-led growth strategy as it continues to develop and commercialise its skin health technologies across cosmetic and supplement markets.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

Spark’s Take on GB:SBTX Stock

According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.

The overall stock score is primarily impacted by the company’s financial performance challenges, including unprofitability and negative cash flows. Technical analysis indicates bearish momentum, and valuation concerns are heightened by a negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.

To see Spark’s full report on GB:SBTX stock, click here.

More about SkinBioTherapeutics

SkinBioTherapeutics plc is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix® platform developed with the University of Manchester. The group targets the skin healthcare market through five pillars, with its most advanced activities in cosmetic skincare, where it partners with Croda plc to supply SkinBiotix® as the active ingredient Zenakine™, and in gut-skin axis food supplements under the AxisBiotix™ brand for inflammatory skin conditions, sold direct-to-consumer, via Amazon and in selected Superdrug stores. It is also pursuing a consolidation strategy through acquisitions in skincare and cosmetic applications to expand distribution, geographic reach and manufacturing capacity, and has been listed on AIM since 2017.

Average Trading Volume: 1,174,280

Technical Sentiment Signal: Strong Sell

Current Market Cap: £36.88M

See more data about SBTX stock on TipRanks’ Stock Analysis page.